Mar 17, 2020
Vivante Health Announces Collaboration with Janssen for Predictive Disease Modeling
Sep 30, 2019
FDA Approves New Drug to Treat Diabetes-Related Kidney Disease
Jun 11, 2019
INVOKANA® (canagliflozin) Significantly Reduced Major Cardiovascular Events and Kidney Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease in New CREDENCE Analysis
Apr 14, 2019
INVOKANA® (canagliflozin) Significantly Reduces the Risk of Renal Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease in the Landmark Phase 3 CREDENCE Study
Mar 28, 2019
Janssen Submits Supplemental New Drug Application to U.S. FDA for INVOKANA® (canagliflozin) for the Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes
Feb 28, 2019
Dr. Guislain Museum and Janssen Seek Global Nominations for Annual "Breaking the Chains of Stigma" Award
Dec 12, 2018
New Phase 3 data demonstrate superiority of TREMFYA® (guselkumab) vs Cosentyx® (secukinumab) in delivering PASI 90 responses in the treatment of moderate to severe plaque psoriasis at week 48
Dec 03, 2018
Updated Data from Phase 1/2 Open-Label Study of BCMA-Directed CAR-T Cell Therapy LCAR-B38M Show Tolerable Safety Profile, High Overall Response and MRD Negative Rate in Treatment of Patients with Advanced Relapsed or Refractory Multiple Myeloma
Dec 03, 2018
IMBRUVICA® (ibrutinib) Plus Obinutuzumab Showed Significant Improvement in Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Oct 09, 2018
The Center for Victims of Torture Receives 2018 Dr. Guislain "Breaking the Chains of Stigma" Award for Providing Psychological Care and Resources for Survivors of Torture
Sep 27, 2018
Janssen Elects Not to Continue Agreement with Geron for Imetelstat
Sep 21, 2018
Janssen Announces Results of Esketamine Nasal Spray Phase 3 Study in Patients with Treatment-Resistant Depression
Sep 10, 2018
Janssen Recognizes World Suicide Prevention Day with New Video Series
Jun 04, 2018
James Allison, Ph.D., Wins 2018 Dr. Paul Janssen Award for Biomedical Research
Jun 03, 2018
Erdafitinib Phase 2 Study Results Show Promise in the Treatment of Metastatic Urothelial Cancer
May 03, 2018
Janssen to Present Data in Treatment-Resistant Depression, Schizophrenia, Health Economics and Outcomes and Population Health at American Psychiatric Association 2018 Meeting
Mar 15, 2018
Janssen Announces U.S. FDA Breakthrough Therapy Designation for Erdafitinib in the Treatment of Metastatic Urothelial Cancer
Sep 06, 2017
Actelion Receives FDA Approval Of TRACLEER® (bosentan) For Use In Pediatric Patients With Pulmonary Arterial Hypertension